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The aim of the study was to evaluate cardiac safety of two different schedules of Epirubicin and Paclitaxel in advanced breast cancer
patients enrolled into a multicenter randomized phase III trial. Patients received Epirubicin 90mgm
 2 plus Paclitaxel 200mgm
 2 (3-h
infusion) on day 1 every 3 weeks for eight courses (arm A), or Epirubicin 120mgm
 2 on day 1 every 3 weeks for four courses
followed by four courses of Paclitaxel 250mgm
 2 on day 1 every 3 weeks (arm B). Left ventricular ejection fraction was evaluated by
bidimesional echocardiography at baseline, after four and eight courses of chemotherapy and every 4 months during follow-up.
Baseline median left ventricular ejection fraction was 60% in arm A and 65% in arm B; after four courses, figures were 57 and 60%,
respectively. After eight courses, the median left ventricular ejection fraction in arm A declined to 50% while no further reduction was
detected in arm B by adding four courses of high-dose Paclitaxel. Seven episodes of congestive heart failure were observed during
treatment in arm A. Present monitoring demonstrated that the risk of congestive heart failure or impairment in the cardiac function
correlated only with the cumulative dose of Epirubicin; no impact on cardiotoxicity can be attributed to high-dose Paclitaxel.
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Anthracyclines (Doxorubicin and Epirubicin) still represent the
most active and widely used cytotoxic drugs in the management of
breast cancer: their introduction in the adjuvant setting provided a
modest, but significant, improvement in survival and their use in
first-line therapy for advanced disease significantly improved
response rate and palliation (A’Hern et al, 1993; EBCTCG, 1998).
However, successful use is limited by their cumulative dose-related
cardiotoxicity, less severe after Epirubicin than after equimolar
doses of the parental compound, Doxorubicin (Cersosimo and
Hong, 1986). In the last decade, the introduction of taxanes
(Paclitaxel and Docetaxel) in the treatment of breast cancer have
provided additional therapeutic options for patients with advanced
disease, and these molecules have been widely tested in combina-
tion with anthracyclines yielding promising results. However,
together with the high rate of remission, some authors underlined
the unexpectedly high incidence of severe cardiotoxic events when
the combination Paclitaxel/Doxorubicin was used. In these cases,
Paclitaxel seemed to be actively responsible for enhanced
cardiotoxicity of the combination since it significantly modified
the pharmacokinetics of Doxorubicin and its cardiotoxic metabo-
lites (Gianni et al, 1995a,b; Gehl et al, 1996). At comparable dose
levels, Epirubicin is significantly less cardiotoxic than Doxorubicin
(Perez et al, 1991) and Paclitaxel seems to play a minor role on
Epirubicin metabolism when the two drugs are used in combina-
tion (Conte et al, 1997, Danesi et al, 2002); this data could explain,
in part, the more favourable cardiotoxic profile reported for the
douplet Paclitaxel/Epirubicin.
More recently, the sequential administration of antiblastic drugs
has attracted the attention of researchers and clinicians. This
alternative schedule of administration is supported by an
interesting preclinical rationale (Norton, 1997); in addition, the
sequence of Epirubicin followed by Paclitaxel (3-h infusion) is also
supported by clinical data showing the partially non cross-
resistance of the two drugs (Gianni et al, 1995a; Seidman et al,
1995). Our group carried out a multicenter randomised phase III
trial testing the safety, activity and efficacy of two different
schedules of Epirubicin and Paclitaxel (concurrent vs sequential)
in advanced breast cancer patients. In both the arms, drugs were
administered at their maximum tolerated doses (not requiring
colony-stimulating factor support) either in combination (Conte
et al, 1997) or as single-agent (Bashtold et al, 1996). The overall
results of sequentially administered Epirubicin and Paclitaxel
seemed to be comparable to those obtained with the combination
of the two drugs (Baldini et al, 2002); however, no data, so far
exists, in literature on the cardiac safety of this alternative
schedule.
The present report concerns the systematical monitoring of
cardiac functions performed in 136 patients enrolled into the
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labove-mentioned randomised trial; we evaluated the relationship
between schedule, cumulative dose of Epirubicin, type of prior
adjuvant treatment and risk of developing a cardiotoxic event.
PATIENTS AND METHODS
Patients
From May 1999 to July 2001, 202 breast cancer patients, from seven
Institutions (six Italian, one Spanish), were enrolled. Bidimension-
ally measurable metastatic disease, ECOG performance status p2,
normal haematologic (haemoglobin 411gdl
 1, wbc44.000ml
 1,
platelet count X100.000ml), hepatic (bilirubin p2  upper
normal limit) and renal (creatinine p2  upper normal limit)
functions were required. Baseline left ventricular ejection fraction
(LVEF) greater than 50% at bidimensional ultrasonography and no
clinical history of cardiac disorders were mandatory. Prior
adjuvant chemotherapy was allowed if stopped at least 1 year
before entering the study; adjuvant Epirubicin-based chemother-
apy was permitted if the cumulative dose did not exceed
360mgm
 2. Patients submitted to prior chemotherapy for
advanced disease were not allowed, and only one hormonal
therapy (adjuvant or advanced) was permitted.
Out of 202 patients, 136 underwent systematic cardiac monitor-
ing performed during treatment and follow-up.
Treatment plan
Patients were randomised to:
Arm A: Epirubicin 90mgm
 2 (bolus i.v.) immediately followed
by Paclitaxel 200mgm
 2 (3-h infusion) on day 1 every 3 weeks for
a maximum of eight courses (EþP).
Arm B: Epirubicin (single agent) 120mgm
 2 (bolus i.v.) on day
1 every 3 weeks for four courses, followed by four courses of
Paclitaxel (single agent) 250mgm
 2 on day 1 every 3 weeks
(E-P).
Evaluation of cardiac function
In both arms, clinical examination and ECG were performed at
baseline and at every two courses of chemotherapy; LVEF was
determined by bidimensional echocardiography on study entry,
after four and eight courses of treatment; cardiac monitoring was
continued every 4 months during follow-up. Toxicity was graded
according to the New York Heart Association (NYHA) criteria for
cardiac failure (NYHA, 1964).
Objective and statistical analysis
The primary end point was the incidence of cardiac events in both
arms. A cardiac event was defined as a 20% decline in LVEF from
baseline or a congestive heart failure (CHF). The diagnostic criteria
for CHF were history of breathlessness, dyspnea, presence of
peripheral oedema, cardiomegaly on chest radiography with or
without pulmonary congestion and pleural effusion. At the
occurrence of clinical symptoms of CHF, a reduced LVEF
contributed to diagnosis. The risk of developing a cardiotoxic
event as a function of cumulative dose of Epirubicin and schedule
was estimated by the Kaplan–Meier method. In order to compare
the risk of development of a cardiac event in two groups, the Log-
rank test was used. Data were analysed using SPSS/PCþ11.5
statistical softwere.
RESULTS
Out of 136 patients, 72 received Epirubicin plus Paclitaxel (564
total courses) and 64 Epirubicin followed by Paclitaxel (492 total
courses). No significant difference in risk factors for heart disease
(age, hypertension, left breast irradiation) was observed between
the two arms. In both groups, about 25% of patients had prior
anthracycline-based adjuvant therapy (Table 1).
After four courses of treatment, in both arms, a modest decrease
in the median LVEF was observed: from 60 to 57% in arm A and
from 65 to 60% in arm B; the median delivered dose of Epirubicin
was 360mgm
 2 (range 90–720mgm
 2) and 480mgm
 2 (range
240–840mgm
 2) in arms A and B, respectively. In arm A, four
additional courses of concomitant EþP induced a further drop of
median LVEF to 50% (median delivered doses of E 720mgm
 2
(range 90–1080mgm
 2)). In arm B, no further reduction in LVEF
was observed by adding, sequentially, four courses of high-dose
Paclitaxel. After four courses of chemotherapy, 12 patients (six for
each arm) showed a 20% decline in LVEF (from baseline): at the
end of the treatment (eight courses), the same reduction was
detected in 17 patients arm A and nine patients arm B (Figure 1).
No episode of CHFs was observed in arm B. Seven episodes of
CHF were reported in arm A: characteristics of the patients are
listed in Table 2. Four out of seven patients had prior Epirubicin-
based adjuvant therapy. One patient (71 years old, no prior
adjuvant anthracycline, no breast radiotherapy) was admitted 10
days after the first course of chemotherapy because of severe
dyspnea: she had pulmonary congestion, a LVEF of 25% (baseline
50%), peripheral oedema and oliguria; a grade 3 neutropenia was
also observed: she died 2 days after admission. Three patients were
admitted a few days after the end of combination therapy (eight
total courses), with clinical signs and symptoms of CHF
(cumulative dose of Epirubicin 1080mgm
 2): a chest X-ray
showed cardiomegaly in two out of three patients and their LVEFs
dropped to 28 and 30%. They were treated with diuretics,
angiotensin converting enzyme (ACE) inhibitors, anti-arrhythmics
and anti-coagulants at first; subsequently, they were stabilised with
digitalo-diuretics therapy and cardioaspirin. These patients died of
disease 16, 24 and 18 months after CHF with persistent severe
impairment in the cardiac function. The last three patients
presented class III CHF (NYHA): one patient had received
adjuvant Epirubicin and three courses of EþP when the
symptoms appeared (cumulative dose of Epirubicin 630mgm
 2),
while the other two were anthracycline-naı ¨ve and showing CHF
after a cumulative dose of 720mgm
 2 (eight total courses) and
360mgm
 2 (four total courses). They required admission because
of dyspnea but no cardiomegaly or peripheral oedema was
detected: their LVEFs were more than 20% reduced from baseline.
After digitalo-diuretic therapy, they recovered completely during
follow-up. All cardiotoxic events were observed during therapy or
immediately after the end of treatment, no episode of cardiac
function impairment was observed during follow-up.
In the whole population (136 patients), the risk of developing an
event was analysed as a function of the cumulative dose of
Table 1 Patients characteristics
E+P E-P
No. % No. %
No. assessable 72 64
Median age (range) 58 (36–73) 58 (30–73)
Median ECOG PS 0 (0–1) 0 (0–1)
Disease status at random
Metastatic ab initio 19 26.4 10 15.7
Relapsed after surgery 53 73.6 54 84.3
Prior adjuvant CT 32 44.4 33 51.5
Epirubicin based 18 25 16 25
PS¼perfofmance status; ECOG¼European Collaborative Oncology Group;
CT¼chemotherapy
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probability of cardiotoxicity was significantly higher in patients
receiving prior adjuvant Epirubicin than in patients treated with
other adjuvant therapies (P¼0.02) (Figure 2). Patients where then
stratified according to the type of prior adjuvant treatment
(Epirubicin based and free) and the impact of the schedule
(concurrent vs sequential) was evaluated in both subgroups: no
statistically significant impact on the risk of cardiac impairment
could be attributed to the schedule and the P-values were 0.30 and
0.36 in patients receiving prior adjuvant anthracycline or other
adjuvant treatment respectively (Figure 3a and b).
DISCUSSION
Anthracyclines (Doxorubicin and Epirubicin) still represent the
cornerstone of breast cancer treatment; originally introduced in
the metastatic setting, they are now widely used postoperatively in
high-risk early breast cancer. Often, in clinical practice, patients
treated with adjuvant anthracycline-based combinations, when
relapsed, undergo a first-line therapy containing the same drug, if
no anthracycline resistance is hypothesised. As a consequence,
most breast cancer patients receive high cumulative dose of these
drugs during their clinical history. Unfortunately, these molecules
cause dose-related cardiotoxicity, mainly consisting in dilated
cardiomiopathy, which is irreversible and can be worsened by
concomitant treatments or diseases. Cardiotoxicity has become a
more important issue in the past decade, with the introduction of
taxanes (Paclitaxel first) in clinical practice often combined with
anthracyclines. The literature has demonstrated a high rate of CHF
when Doxorubicin and Paclitaxel are administered in combination,
while the douplet Epirubicin/Paclitaxel can be more safely
administered with no excess of cardiotoxicity.
This study reports the results of a prospective evaluation of the
cardiac safety of two different schedules of Epirubicin and
Paclitaxel. The element that makes the cardiac monitoring we
performed different from those published in literature is that,
according to the selection criteria, the patients enrolled into this
multicenter randomised trial may have received prior Epirubicin-
based adjuvant therapy: this subgroup is more and more
represented in clinical practice. Considering that 25% of the
patients randomised had received prior adjuvant Epirubicin, so as
to undergo high cumulative doses of this drug, the percentage of
CHFs observed (seven out of 136 patients 5%) as well as the
percentage of asymptomatic 20% reduction in LVEF (13.9%) were
actually quite low. However, it is important to note that most of the
events were registered in patients receiving combination therapy
(17 vs 9) and all the episodes of CHFs were observed with EþP( 7
vs 0); as a matter of fact, according to the study design, the planned
cumulative dose of Epirubicin is higher in arm A (720mgm
 2)
than in arm B (480mgm
 2). In agreement with this, the
cumulative dose of Epirubicin received by the patients (adjuvant
therapy plus advanced) is the only statistically significant risk
factor for cardiotoxicity emerging from our analysis: this risk is
consistent whatever the interval of time between the two strategies,
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Figure 1 Incidence of cardiac events by treatment arm.
Table 2 Characteristics of patients with CHF
E+P
Number of patients 7
Age (years) 71 67 61 46 56 46 70
PS (ECOG) 1 0 0 0 0 0 0
Prior adjuvant E (360mgm
 2) No Yes No Yes Yes Yes No
Left breast radiotherapy No Yes Yes Yes Yes Yes Yes
Baseline LVEF (%) 50 58 60 50 55 55 55
CHF class NYHA IV III III IV IV IV III
E cumulative dose (mgm
 2) 90 630 720 1080 1080 1080 360
Death due heart failure Yes No No No No No No
CHF¼congestive heart failure; LVEF¼left ventricular ejection fraction; NY-
HA¼New York Heart Association. PS¼performance status; ECOG¼European
Collaborative Oncology Group
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land constantly rises as the number of Epirubicin administrations
increase.
After stratification of patients according to the type of adjuvant
treatment (anthracycline based and free), we observed that the
schedule (combined vs sequential) ‘per se’ did not significantly
affect the risk of cardiotoxicity. However, despite the lack of
statistical significance, probably due to the limited number of
cardiac events registered, the trends, we observed, are different in
the different subpopulations. While in anthracycline-naı ¨ve patients
the cardiac risk is quite low whatever may be the randomisation
arm, according to the published data on the safety of concomitant
Epirubicin/Paclitaxel (Conte et al, 1997), in patients previously
exposed to adjuvant Epirubicin and randomised to receive EþP,
the risk of cardiotoxicity gradually increases during chemotherapy,
and from 20% after the fourth course, it rises steeply to 75% or
more after the eighth course (cumulative dose 1080mgm
 2 in
some patients). On the contrary, patients randomised to E-P
showed a modest increase in cardiotoxicity during the four initial
courses of high-dose Epirubicin (up to 21%), but the risk
stabilizes, and no additional event was reported during, or after,
four courses of high-dose Paclitaxel (250mgm
 2). This strongly
suggests that taxane, in both arms, has no impact on cardiotoxic
events.
The preliminary clinical results of our randomised trial seemed
to suggest that the two approaches (concurrent and sequential)
were able to give the same benefit (Baldini et al, 2002). In terms of
activity, EþP provided an earlier opportunity to achieve a
complete response: after four courses of therapy, the complete
response rates were 4.7 vs 1.1 in arm A and B, respectively
(P¼0.22). However, at the end of treatment (eight courses), no
difference either in the complete (11.3 vs 11%) or overall response
rate (58 vs 57%) was observed. Overlapping results were also
obtained in terms of time to progression and overall survival.
While compliance to both strategies was also similar, they
significantly differed only for nonhaematologic toxicity, for
cardiotoxicity in particular: the risk of CHF and cardiac
impairment was higher in the combination arm and especially
for Epirubicin pretreated patients. In clinical practice, this data
should be taken into account, together with other issues
(symptomatic control, quality of life and clinical benefit) when
planning a taxane-based strategy in metastatic patients previously
exposed to anthracycline. In the light of the equivalence of the two
approaches, for this large subgroup, the sequence Epirubicin/
Paclitaxel could certainly be a reasonable choice.
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